A detailed history of Victory Capital Management Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 63,742 shares of ITCI stock, worth $5.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,742
Previous 68,139 6.45%
Holding current value
$5.3 Million
Previous $4.67 Million 0.13%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$67.99 - $80.84 $298,952 - $355,453
-4,397 Reduced 6.45%
63,742 $4.66 Million
Q2 2024

Aug 05, 2024

BUY
$64.76 - $79.84 $302,688 - $373,172
4,674 Added 7.36%
68,139 $4.67 Million
Q1 2024

May 03, 2024

SELL
$64.37 - $75.65 $160,345 - $188,444
-2,491 Reduced 3.78%
63,465 $4.39 Million
Q4 2023

Feb 05, 2024

SELL
$46.37 - $73.65 $70,621 - $112,168
-1,523 Reduced 2.26%
65,956 $4.72 Million
Q3 2023

Nov 06, 2023

SELL
$52.09 - $64.1 $42,609 - $52,433
-818 Reduced 1.2%
67,479 $3.51 Million
Q2 2023

Jul 27, 2023

SELL
$54.67 - $66.44 $67,462 - $81,986
-1,234 Reduced 1.77%
68,297 $4.32 Million
Q1 2023

May 02, 2023

SELL
$43.8 - $56.99 $1.68 Million - $2.19 Million
-38,349 Reduced 35.55%
69,531 $3.77 Million
Q4 2022

Feb 10, 2023

SELL
$44.07 - $54.45 $21,241 - $26,244
-482 Reduced 0.44%
107,880 $5.71 Million
Q4 2022

Feb 09, 2023

SELL
$44.07 - $54.45 $8.24 Million - $10.2 Million
-187,033 Reduced 63.32%
108,362 $5.73 Million
Q3 2022

Nov 02, 2022

SELL
$42.7 - $59.99 $35.8 Million - $50.4 Million
-839,455 Reduced 73.97%
295,395 $13.7 Million
Q2 2022

Aug 01, 2022

BUY
$43.0 - $65.64 $8.71 Million - $13.3 Million
202,528 Added 21.72%
1,134,850 $64.8 Million
Q1 2022

May 04, 2022

BUY
$38.74 - $62.09 $36.1 Million - $57.9 Million
932,322 New
932,322 $56.9 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.85B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.